MSLN Targeted Drugs Entering the Fast Lane
Since December 2023, there have been several positive updates about drugs targeting MSLN. On December...
Feb 29, 2024
Base editing technology leads a new chapter in drug development
Since its debut in 2016, base editing technology has opened up new perspectives and methods...
Feb 14, 2024
Deciphering LY6G6D - An Emerging Target in Colorectal Cancer
Colorectal cancer (CRC) is recognized as one of the most common and life-threatening malignancies, with...
Feb 07, 2024
RNP, an emerging powerful tool for gene delivery
Through decades of rapid development, gene editing technology has officially entered the CRISPR 2.0 era,...
Feb 02, 2024
PepTalk 2024 in San Diego
KACTUS will be exhibiting at PepTalk San Diego at booth #217. Stop by our booth to...
Jan 04, 2024
Focusing on the Neuroendocrine Tumor Target SEZ6
Neuroendocrine neoplasms/tumors (NENs or NETs) are rare tumors that originate from specialized cells called neuroendocrine...
Jan 02, 2024
Butyrophilin (BTN) family: γδ T Cell Receptor Ligands, Immunomodulators and More
Immunotherapy is an essential option for current disease treatment. However, most patients fail to respond...
Dec 27, 2023